Liver cancer outcomes: viral hepatitis with fatty liver
Part of Cancer, Digestive system clinical trials.
This study looks at how liver cancer (hepatocellular carcinoma) progresses and responds in people who have a history of viral hepatitis (hepatitis B or C) and also have a fatty liver condition (MASLD). It aims to understand whether having both conditions changes survival compared with having only viral hepatitis. If you have liver cancer and either viral hepatitis or both conditions, this study could help tailor your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (HCC).
- You have a history of chronic hepatitis B or C infection.
- You have a fatty liver condition (MASLD), confirmed by a scan (FibroScan or ultrasound) and at least one metabolic risk factor (such as obesity, type 2 diabetes, or high blood pressure).
- You are able and willing to give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study tests a new way to find liver cancer early in people who are at higher risk, using regular ultrasound and blood tests. If you qualify, you'll get close monitoring to catch any problems sooner, which may improve treatment options.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.